Stämm unveils revolutionary bioreactor technology for antibody production

In January 2025, pilot runs were completed in Europe and South America, showcasing the enhanced efficiency of Stämm's continuous bioreactor designed specifically for monoclonal antibody production. The trials that took place in Germany, Switzerland, and Argentina demonstrated a remarkable increase in volumetric productivity, achieving a minimum of 15 times greater output than traditional methods—projecting up to 50 times in the coming year. The implementation timeline of less than three months for these pilots signals a crucial step forward in biomanufacturing capabilities, especially for cell and gene therapies. The bioreactor's design boasts of a low shear stress environment, high gas exchange, and the utilization of single-use 3D-printed cartridges promoting scalability and cost efficiency, thus elevating the biomanufacturing standards. This advancement in bioprocess technology is particularly timely as the industry faces a patent cliff, which necessitates urgent innovations to sustain the production of biologics. Stämm, through its novel approach, is positioning itself as an ideal partner to bridge the gaps in accessibility and repeatability within the biomanufacturing sector. Leveraging partnerships with early adopters, Stämm's continuous bioreactor could unlock new avenues for next-generation medicines while fostering innovation across the industry, thereby positively impacting the lives of many. The outcomes of these pilot studies not only indicate economic benefits but also highlight the importance of a stress-free production environment that is critical for maintaining the quality of biologics.